CAS 1210344-57-2
:Ertugliflozina
Descripción:
Ertugliflozina es un medicamento que se utiliza principalmente en el manejo de la diabetes mellitus tipo 2. Pertenece a la clase de fármacos conocidos como inhibidores del cotransportador de sodio-glucosa 2 (SGLT2), que funcionan al prevenir la reabsorción de glucosa en los riñones, promoviendo así su excreción en la orina y reduciendo los niveles de glucosa en sangre. La fórmula química de Ertugliflozina refleja su estructura, que incluye un grupo glucosa unido a un sistema de anillo aromático específico. Este compuesto se caracteriza por su capacidad para mejorar el control glucémico y también puede contribuir a la pérdida de peso y a beneficios cardiovasculares en pacientes diabéticos. Además, se ha estudiado Ertugliflozina por sus posibles efectos en la función renal. Los efectos secundarios comunes pueden incluir infecciones del tracto urinario e infecciones micóticas genitales, que están asociadas con un aumento de glucosa en la orina. Al igual que con cualquier medicamento, es esencial que los pacientes consulten a profesionales de la salud para obtener asesoramiento personalizado y monitoreo mientras utilizan Ertugliflozina.
Fórmula:C22H25ClO7
InChI:InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
Clave InChI:InChIKey=MCIACXAZCBVDEE-CUUWFGFTSA-N
SMILES:O[C@H]1[C@@]2(O[C@@](CO)(CO2)[C@@H](O)[C@@H]1O)C3=CC(CC4=CC=C(OCC)C=C4)=C(Cl)C=C3
Sinónimos:- (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-<span class="text-smallcaps">L</span>-idopyranose
- Cc-212
- Mk 8835
- Pf 04971729-00
- Pf-04971729
- β-<span class="text-smallcaps">L</span>-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
- Ertugliflozin
- β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
- PF04971729;PF 04971729 (ERTUGLIFLOZIN)
- Ertugliflozin Base
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose PF-04971729(Ertugliflozin)
- PF-04971729/Ertugliflozin
- (1S,2S,3S,4R,5S)-(2,3,4-TRIS-BENZYLOXY-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL)-68-DIOXA-BICYCLO(3.2.1)OCT-1-YL)-METHANOL
- Ertugliflozin, >=98%
- (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- Ertugliflozin/PF-04971729
- PF-04971729 USP/EP/BP
- CS-186
- ERTUGLIFLOZIN;PF04971729;PF 04971729
- Ertugliflozin : PF 04971729-00
- Leuco methylthioninium
- Ertugliflozin MK-8835
- Ver más sinónimos
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Encontrado 7 productos.
1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
CAS:Fórmula:C22H25ClO7Pureza:98%Forma y color:SolidPeso molecular:436.8827(1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-Ethoxybenzyl)Phenyl)-1-(Hydroxymethyl)-6,8-Dioxabicyclo[3.2.1]Octane-2,3,4-Triol
CAS:(1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-Ethoxybenzyl)Phenyl)-1-(Hydroxymethyl)-6,8-Dioxabicyclo[3.2.1]Octane-2,3,4-TriolPureza:98%Peso molecular:436.88g/molErtugliflozin
CAS:PF-04971729 (Ertugliflozin (PF-04971729)) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2).Fórmula:C22H25ClO7Pureza:99.89% - 99.96%Forma y color:SolidPeso molecular:436.88Ertugliflozin (PF 04971729)
CAS:<p>Ertugliflozin is a novel, selective, and potent inhibitor of SGLT2. It is being developed for the treatment of type 2 diabetes and associated conditions such as hypertension, dyslipidemia and cardiovascular complications. Ertugliflozin selectively inhibits the renal glucose transporter SGLT2 to reduce urinary glucose excretion. In clinical trials ertugliflozin has been shown to significantly lower HbA1c levels in patients with type 2 diabetes mellitus. The drug was well tolerated in clinical trials with no clinically relevant adverse events observed. This agent has also been shown to decrease blood pressure in patients with type 2 diabetes mellitus and normotensive subjects.</p>Fórmula:C22H25ClO7Pureza:Min. 96 Area-%Forma y color:White Off-White PowderPeso molecular:436.88 g/mol





